Analyst Ratings for Array BioPharma and Peers in January 2018
Array BioPharma (ARRY) is a biopharmaceutical company focused on discovery, development, and commercialization of small molecule drugs for the treatment of patients suffering from cancer. Of the nine analysts covering Array BioPharma (ARRY) in January 2018, eight have given the stock a “buy” or higher rating, and one has given it a “hold.” The mean rating for the stock is 1.78 with a target price of $16.22. Array BioPharma makes up 1.9% of the SPDR S&P Biotech ETF’s (XBI) total portfolio holdings.